Aclaris Therapeutics, Inc. (ACRS)
Company Info
ISIN | US00461U1051 |
---|---|
CUSIP | 00461U105 |
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | $81.56M |
---|---|
EPS | -$1.27 |
PEG Ratio | -0.13 |
Revenue (TTM) | $31.25M |
Gross Profit (TTM) | -$60.02M |
EBITDA (TTM) | -$117.57M |
Year Range | $0.59 - $11.12 |
Target Price | $1.80 |
Short % | 9.91% |
Short Ratio | 4.32 |
Share Price Chart
Loading data...
Compare to other instruments
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Aclaris Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Aclaris Therapeutics, Inc. had a return of 20.00% year-to-date (YTD) and -84.33% in the last 12 months.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | 20.00% | 10.04% |
1 month | 4.13% | 3.53% |
6 months | -81.08% | 22.79% |
1 year | -84.33% | 32.16% |
5 years (annualized) | -26.84% | 13.15% |
10 years (annualized) | N/A | 10.96% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 10.48% | 2.59% | ||||||||||
2023 | -24.21% | -8.42% | -27.30% | -82.44% | 20.04% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
This table presents risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
Aclaris Therapeutics, Inc. | -0.74 | ||||
S&P 500 | 2.76 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aclaris Therapeutics, Inc. was 98.05%, occurring on Nov 13, 2023. The portfolio has not yet recovered.
The current Aclaris Therapeutics, Inc. drawdown is 96.18%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-98.05% | Apr 18, 2017 | 1656 | Nov 13, 2023 | — | — | — |
-49.56% | Dec 23, 2015 | 63 | Mar 24, 2016 | 173 | Nov 29, 2016 | 236 |
-19.68% | Dec 19, 2016 | 34 | Feb 7, 2017 | 13 | Feb 27, 2017 | 47 |
-13.11% | Nov 24, 2015 | 7 | Dec 3, 2015 | 9 | Dec 16, 2015 | 16 |
-12.04% | Mar 7, 2017 | 11 | Mar 21, 2017 | 18 | Apr 17, 2017 | 29 |
Volatility
Volatility Chart
The current Aclaris Therapeutics, Inc. volatility is 23.07%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |